“Likely” Merck Consumer Health Sale Could Bring $8 Billion – Analysts
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck executives shift their position about the potential divestiture of the company’s non-pharma assets, including the consumer health business. J.P. Morgan analysts expect a sale of the consumer unit and say Merck’s brands, including Claritin and Coppertone, could grow globally with a new owner.
You may also be interested in...
Novartis Seems Close to Consumer Health Sale – Analyst
Novartis CEO Joe Jimenez made clear the firm is considering divesting its consumer product, animal health and vaccines and diagnostics business, Sanford and Bernstein analysts say. “It seems that Novartis will be making final decisions with these units fairly soon,” they say.
Merck Reaffirms Commitment To Consumer Care In Restructuring
Merck says it remains committed to retaining consumer care and animal health, though it continues to evaluate the businesses. Competitors such as Pfizer and Bristol-Myers Squibb successfully spun out non-pharma assets following similar restructurings.
Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.